The Rise of GLP-1 Receptor Agonists in UK Obesity Treatment
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs), such as semaglutide (marketed as Ozempic or Wegovy) and tirzepatide (Mounjaro or Zepbound), have revolutionised obesity management in the United Kingdom. These injectable medications mimic gut hormones that regulate appetite, slow gastric emptying, and promote insulin secretion, leading to significant weight reduction in many users. In the UK, where obesity affects over 64% of adults according to NHS data, demand has surged, with at least 1.6 million people trying these drugs in the past year, mostly through private channels. The NHS offers them selectively to patients with BMI over 35 and comorbidities, but rollout is expanding amid trials showing 15-20% average weight loss.
Despite their promise, responses vary widely: some lose 20% body weight, others under 5%, prompting questions about underlying causes. Recent research highlights genetics as a contributing factor, aligning with UK higher education efforts in pharmacogenomics—the study of how genes affect drug responses.
Understanding Variability in Weight-Loss Outcomes
Clinical trials like STEP and SURMOUNT demonstrate average losses of 12-22%, but real-world data reveals heterogeneity. About 32% achieve less than 5% reduction, influenced by adherence, diet, exercise, and biology. Non-genetic elements—sex (women lose more), dose, duration, and type 2 diabetes status—account for 21% of variance. UK universities, including Cambridge and Glasgow, emphasise holistic factors, with experts noting behavioural support's role.
This variability burdens the NHS, costing £6.5 billion yearly on obesity-related issues. Identifying predictors could optimise prescriptions, reducing trial-and-error.
Breakthrough Findings from Genome-Wide Association Study
A landmark study published in Nature on April 8, 2026, analysed self-reported data from 27,885 GLP-1 users via 23andMe, identifying genetic links to efficacy and side effects. Focusing on 15,237 European-ancestry participants, researchers conducted GWAS on BMI change (ΔBMI%) and gastrointestinal issues.Read the full study here.
Key discovery: Missense variant rs10305420 in GLP1R (p.Pro7Leu) boosts efficacy, with each T allele adding -0.641% ΔBMI (~0.76kg loss), doubling for homozygotes. Replication in All of Us cohort confirmed (P=0.001). UK Biobank replication was limited by data timing.
Genetic Variants Linked to Side Effects
GLP1R variants rs11760106 and rs9357296 heightened nausea/vomiting odds (OR=1.57 and 1.36), correlating with greater loss, suggesting side effects signal efficacy. For tirzepatide, GIPR variant rs1800437 (p.Glu354Gln) increased vomiting risk (OR=1.84 per C allele), independent of weight loss. Homozygous risk at both loci raised tirzepatide vomiting odds 14.8-fold.
| Variant | Gene | Effect | Drug | Impact |
|---|---|---|---|---|
| rs10305420 (T) | GLP1R | Increased weight loss | GLP-1 RAs | -0.76kg/allele |
| rs1800437 (C) | GIPR | Increased vomiting | Tirzepatide | OR=1.84 |
| rs11760106 (T) | GLP1R | Increased vomiting | GLP-1 RAs | OR=1.57 |
Combined models predict 25% efficacy variance, mostly non-genetic.
UK University Experts Weigh In
Dr. Marie Spreckley from the University of Cambridge called effects "small in clinical terms," stressing non-genetic dominance.Guardian interview. Prof. Naveed Sattar (University of Glasgow) deemed findings "scientifically interesting" but distant from practice, urging trials.
Cambridge's obesity genetics programme, including protective variants discovery (2019), positions UK unis centrally.
Non-Genetic Contributors to Response Variation
- Sex: Women average 12.2% loss vs. 10% men.
- Drug/Dose: Tirzepatide outperforms semaglutide; higher doses enhance loss.
- Duration: Median 8 months yields 11.7% loss.
- Comorbidities: Type 2 diabetes reduces efficacy by 2.87%.
UK research at Imperial College, where Prof. Stephen Bloom pioneered GLP-1, underscores lifestyle integration.
Implications for UK Pharmacogenomics Research
UK leads in pharmacogenomics via Genomics England and MHRA's 2025 GLP-1 pancreatitis study using Yellow Card Biobank saliva samples. Universities like Glasgow's PHOENIX project explore gene-drug interactions. Brunel's 2023 study linked genes to dietary responses in severe obesity.
Integrating genetics could tailor NHS prescriptions, cutting £ billions in ineffective treatments.
UK's Obesity Landscape and GLP-1 Role
Obesity prevalence: 28% adults obese, projected 50% by 2035. GLP-1s offer hope, but access inequities persist—95% private users. Oxford research shows rapid regain post-discontinuation, akin to diets.
Challenges in Implementing Genetic Testing
- Cost: Routine genotyping unaffordable now.
- Equity: European bias in data; less effect in non-Europeans.
- Regulation: NHS needs evidence for guidelines.
- Ethics: Privacy in genetic data.
Manchester's tirzepatide studies address real-world gaps.
Future Outlook: Precision Obesity Medicine in UK Higher Education
UKRI funding pharmacogenomics; collaborations with pharma (Novo Nordisk, Eli Lilly) at unis like Edinburgh, Sheffield. Trials integrating polygenic scores promise 30% better predictions. By 2030, genetic profiling could standardise GLP-1 use, boosting outcomes.
Stakeholders: NHS eyes cost-savings; patients seek personalised plans; academics drive innovation.
Photo by julien Tromeur on Unsplash
Actionable Insights for Researchers and Clinicians
Test GLP1R rs10305420 in trials; combine with lifestyle. UK postdocs in genetics/pharma thrive amid demand—explore opportunities at leading unis.
